

3012

1103326-028233  
5/9/03**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants : Cederberg et al.  
Serial No. : 08/945,425  
Filed : October 21, 1997  
For : ADMINISTRATION OF PHARMACEUTICALS  
Examiner : Desai, R.  
Group Art Unit : 1612

**FAX RECEIVED**

MAY 08 2003

**GROUP 1600****OFFICIAL****CERTIFICATE OF TRANSMISSION UNDER 37 C.F.R. 1.8**

I hereby certify that this paper is being facsimile transmitted to the U.S. Patent and Trademark Office on the date indicated below at the facsimile number 703-308-4556.

Andrew Fessak

48,528

Agent Name

PTO Reg. No.

Andrew fessak

5/7/03

Signature

Date of Signature

Assistant Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

ATTENTION: **Examiner R. Desai**  
FACSIMILE NO: **703-308-4556**  
DATE: **May 7, 2003**  
PAGES: **5 pages**

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT  
UNDER 37 C.F.R. §1.97(c)**

Sir:

Applicants submit this communication and the attached Form PTC-1449 in compliance with 37 C.F.R. §§1.56, 1.97 and 1.98. A copy of the document listed on the Form PTO-1449 is enclosed as part of this communication.

Serial No. 08/945,425, filed Oct. 21, 1997

Docket No. 1103326-0282

Page 2 of 3

The document listed on Form PTO-1449, CN 1080168, was first cited in an Office Action from the Chinese Patent Office during the examination of the Chinese member of the same patent family as the instant application. The Chinese Office Action was issued not more than 3 months from the filing date of this Information Disclosure Statement.

As part of this communication, Applicants are providing an English-language abstract of CN 1080168 listed on Form PTO-1449.

Consideration of the document listed on Form PTO-1449 is respectfully requested.

**TIME OF TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**

This Information Disclosure Statement is being filed after the period specified in 37 C.F.R. §1.97(b) but before the mailing date of either:

- (1) a final action under §1.113 or
- (2) a notice of allowance under §1.311,

whichever occurs first.

**STATEMENT OR FEE**

Accompanying this Information Disclosure Statement is

A.  a statement as specified in 37 C.F.R. §1.97 (e)(1).

**OR**

B.  the fee set forth in 37 C.F.R. §1.17(p) for submission of an information disclosure statement under §1.97(c). (\$180.00).

Sesial No. 08/945,425, filed Oct. 21, 1997

Docket No. 1103326-0282

Page 3 of 3

**STATEMENT UNDER 37 C.F.R. § 1.97(e)(1)**

I hereby state that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.

No fee should be due in connection with this communication. If any fee is due, the Assistant Commissioner is authorized to charge the fee to Deposit Account No. 23-1703.

Dated: May 7, 2003

Respectfully submitted,

Andrew Fessak

Andrew Fessak  
Reg. No. 48,528  
Agent for Applicant

Customer No. 007470  
White & Case LLP  
Agent's Direct Dial: (212) 819-8437